At a glance
ClinicalIndex Comparison RecordN/ACompleted· 90 enrolled
Drug / intervention
Microencapsulated Sublingual Glycine (MSG) +1 moredietary
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Effects of Microencapsulated Sublingual Glycine (Bidicin) on Cognitive Performance in Healthy Men After an Acute Stressor - a Randomized, Partly Double-blind Placebo-controlled Clinical Trial
In Brief
A clinical study evaluating Microencapsulated Sublingual Glycine (MSG) and Placebo for Healthy and 2 related conditions. Completed, enrolled 90 participants across 1 site.
Detailed Summary
The aim of this study is to assess whether intake of Glycine (MSG) leads to an increase of cognitive performance after an acute stressor compared to placebo. One group will receive verum, one group placebo and one group will not receive any intervention. Cognitive testing will be performed in connection with the Trier Social Stress Test (TSST).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy, Stress, Psychological, Cognitive Impairment
CountriesGermany
CollaboratorsOOO MNPK BIOTIKI
Timeline
N/ACompletedFinished
201820192020202120222023202420252026
Enrollment StartNov 2017
First PostedNov 2017
Primary CompletionMar 2018
Study CompletionJun 2018
TodayJul 2026
First PostedNov 27, 2017
Enrollment StartNov 15, 2017
Primary CompletionMar 15, 2018
Study CompletionJun 15, 2018
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 8.6 years ago
Interventions
Microencapsulated Sublingual Glycine (MSG)dietary
Glycine (MSG) tablet
Placebodietary
Lactose tablet manufactured to mimic Glycine (MSG) tablet